Cardiac amyloidosis in the practice of a cardiologist and therapist. Case report
- Authors: Nikiforova T.V.1, Magomedova Z.М.1,2, Magaramova M.F.1, Pershina E.S.1,2, Shchekochikhin D.Y.1, Andreev D.A.1
-
Affiliations:
- Sechenov First Moscow State Medical University (Sechenov University)
- Pirogov City Clinical Hospital
- Issue: Vol 27, No 1 (2025): Cardiology and Nephrology
- Pages: 32-37
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/286413
- DOI: https://doi.org/10.26442/20751753.2025.1.203105
- ID: 286413
Cite item
Full Text
Abstract
Amyloidosis is a heterogeneous group of diseases associated with abnormal protein aggregation and deposition in organs and tissues as insoluble fibrils. The heterogeneity of the clinical manifestations of these disorders is due to various precursor proteins and damage to various organs and systems. Diagnosis of the disease is complex and requires high clinical alertness from physicians. Unfortunately, in most cases, the patient's diagnostic path is unreasonably long, and the effectiveness of therapy is primarily determined by the timing of diagnosis. Often, the cardiologist is the first specialist to be approached by a patient with this severe disease. The article highlights approaches to early diagnosis of amyloidosis with heart involvement.
Full Text
##article.viewOnOriginalSite##About the authors
T. V. Nikiforova
Sechenov First Moscow State Medical University (Sechenov University)
Author for correspondence.
Email: attrcmp@gmail.com
ORCID iD: 0000-0003-3072-8951
Graduate Student
Russian Federation, MoscowZ. М. Magomedova
Sechenov First Moscow State Medical University (Sechenov University); Pirogov City Clinical Hospital
Email: attrcmp@gmail.com
ORCID iD: 0000-0001-6753-1525
Graduate Student
Russian Federation, Moscow; MoscowM. F. Magaramova
Sechenov First Moscow State Medical University (Sechenov University)
Email: attrcmp@gmail.com
ORCID iD: 0009-0005-1889-5249
Graduate Student
Russian Federation, MoscowE. S. Pershina
Sechenov First Moscow State Medical University (Sechenov University); Pirogov City Clinical Hospital
Email: attrcmp@gmail.com
ORCID iD: 0000-0002-3952-6865
Cand. Sci. (Med.), Assoc. Prof.
Russian Federation, Moscow; MoscowD. Yu. Shchekochikhin
Sechenov First Moscow State Medical University (Sechenov University)
Email: attrcmp@gmail.com
ORCID iD: 0000-0002-8209-2791
Cand. Sci. (Med.)
Russian Federation, MoscowD. A. Andreev
Sechenov First Moscow State Medical University (Sechenov University)
Email: attrcmp@gmail.com
ORCID iD: 0000-0002-0276-7374
D. Sci. (Med.)
Russian Federation, MoscowReferences
- Vaxman I, Gertz MA. Worldwide Perspectives of Amyloidosis. Acta Haematol. 2020;143(4):301-3. doi: 10.1159/000509736
- Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583-96.
- Schleiden J. M. Scientific botany. First book: chemistry of Plants. 1842.
- Sipe JD, Cohen AS. Review: history of the amyloid fibril. J Struct Biol. 2000;130(2-3):88-98. doi: 10.1006/jsbi.2000.4221
- Virchow R. Lecture XVII. Amyloid degeneration. Inflammation. Cellular Pathology as Based Upon Physiological and Pathological Histology. 1971; p. 409-37.
- Buxbaum JN, Eisenberg DS, Fändrich M, et al. Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2024:1-8. doi: 10.1080/13506129.2024.2405948
- Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol. 2015;24(6):343-50. doi: 10.1016/j.carpath.2015.07.008
- Yazaki M, Liepnieks JJ, Barats MS, et al. Hereditary systemic amyloidosis associated with a new apolipoprotein AII stop codon mutation Stop78Arg. Kidney Int. 2003;64:11-6. doi: 10.1046/j.1523-1755.2003.00047.x
- Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021;42(16):1554-68. doi: 10.1093/eurheartj/ehab072
- Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004;22(18):3751-7. doi: 10.1200/JCO.2004.03.029
- Vaxman I, Gertz M. When to Suspect a Diagnosis of Amyloidosis. Acta Haematol. 2020;143(4):304-11. doi: 10.1159/000506617
- Cuddy SAM, Falk RH. Amyloidosis as a systemic disease in context. Can J Cardiol. 2020;36(3):396-407. doi: 10.1016/j.cjca.2019.12.033
- Gertz MA. Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment. Am J Hematol. 2024;99(2):309-24. doi: 10.1002/ajh.27177
- Writing Committee; Kittleson MM, Ruberg FL, et al. 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2023;81(11):1076-126. doi: 10.1016/j.jacc.2022.11.022
- Lindmark K, Pilebro B, Sundström T, Lindqvist P. Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic. ESC Heart Failure. 2021;8(1):745-9. doi: 10.1002/ehf2.13110
Supplementary files
